Development asset linked to Talon Biomarkers in public FDA and regional records.
pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
Talon Biomarkers
Talion
Talon Biomarkers drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Whippany, USA HQ
2021 Founded
7 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Whippany, USA
- Founded
- 2021
- Employees
- 7
- Programs
- 5
- Drugs
- 44
- Patents
- 0
Talon Biomarkers pipeline
Portfolio lens on 44 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Talon Biomarkers drug portfolio — 44 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Talon Biomarkers's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Thyroid peroxidase.
- Target
- Thyroid peroxidase
- Mechanism
- Thyroid peroxidase inhibitor
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bile acid receptor.
- Target
- Bile acid receptor
- Mechanism
- Bile acid receptor FXR agonist
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.
-
Development asset linked to Talon Biomarkers in public FDA and regional records.